Advanced Search

Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2015 June;63(3) > Minerva Cardioangiologica 2015 June;63(3):205-16



A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


Minerva Cardioangiologica 2015 June;63(3):205-16


Transcatheter Aortic Valve Implantation Experience with SAPIEN 3

Ohno Y. 1, 2, Tamburino C. 1, 3, Barbanti M. 1

1 Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy;
2 Department of Cardiology, University of Tokai School of Medicine, Isehara, Japan;
3 Excellence Through Newest Advances (ETNA) Foundation, Catania, Italy

Based on randomized trials with first generation devices, transcatheter aortic valve replacement (TAVI) has been included into the treatment strategy for high-risk and inoperable patients with severe aortic stenosis. Procedural complications remain a concern with TAVI, including stroke, vascular complications, paravalvular leak (PVL) and conduction disturbances. Addressing these limitations will support TAVI use in lower risk populations. This review discussed features and most recent clinical evidence of the new balloon-expandable THV (SAPIEN 3, Edwards Lifescience, Irvine, CA, USA).

language: English


top of page